Early detection of cardiovascular-renal-metabolic conditions: from silent to seen
Join us for an enriching discussion on curbing the significant burden of cardiovascular-renal-metabolic (CRM) conditions.
Building on recent and upcoming global commitments on these interconnected conditions, the session will explore practical actions for countries to drive integrated CRM care for patients. There will be a particular focus on improving early screening and diagnosis of chronic kidney disease (CKD) and steatotic liver disease (SLD), which are often silent until advanced stages and co-exist with and amplify other CRM conditions.
This session on the sidelines of the World Health Assembly in Geneva will bring together perspectives from the advocacy sector, academia, governments, and industry.
Our expert panel will discuss topics such as:
What it will take to scale up early screening and detection of CRM conditions
The barriers and opportunities for improved care for CRM conditions
How global commitments, including on CKD, SLD and other areas can be implemented in an integrated way for long-term impact
Speakers will include:
Daniel Gallego – President, European Kidney Patient's Federation
Neil Johnson - Executive Director, Global Heart Hub
Richard Sloggett - Founder and Programme Director, Future Health Research
Sandy Sommer - Corporate Senior Vice President, Head of Therapeutic Area Cardiovascular, Renal & Metabolic, Boehringer Ingelheim
This event is organized by Boehringer Ingelheim - please click here to check out all of our events at the 79th World Health Assembly